|
|
|
|
TLK286
A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called glutathione analogs. (National Cancer Institute)
Telik Announces Quarterly Financial Release, Conference Call and ... Feb 17, 2005
The company's most advanced drug development candidate is TELCYTA(TM) (TLK286), a tumor-activated small molecule product candidate which is in Phase 3 ... PR Newswire (press release)
Telik Announces Fourth Quarter and 2004 Year End Financial Results Feb 24, 2005
The increase in expenses in 2004 compared to 2003 was due to expanded clinical development of TELCYTA(TM) (TLK286) and TELINTRA(TM) (TLK199) and increased ... PharmaLive.com (press release),
... Go to the Article Feb 18, 2005
The drug Telcyta™ (TLK286) is being tested as the possible new standard treatment for some advanced ovarian cancer patients based on a previous study showing ... CancerWise
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
<**results**>
Telik Initiates First Triplet Combination Trial With Telcyta in ... Jun 30, 2004
...(Nasdaq: TELK - News) announced the initiation of a new Phase 2 clinical trial in which TELCYTA(TM) (TLK286) will be evaluated in combination with carboplatin ... Yahoo News (press release) -
Resources from the National Cancer Institute on TLK286:
|
|
|
